- Company
- Expanded indication for Jardiance
- by jung, sae-im May 29, 2022 05:15pm
- The SGLT-2 inhibitor Jardiance expanded the indication to HFpEF. Beringer Ingelheim Korea and Lilly Korea announced on the 26th that Jardiance has been approved by the MFDS to expand its indication as a treatment for chronic heart failure regardless of left ventricular contraction function (hereinafter referred to as heart rate). Jardiance wa
- Company
- Lorviqua, which is about to be reimbursed, has settled
- by Eo, Yun-Ho May 29, 2022 05:15pm
- The third-generation ALK inhibitor Lorviqua has settled in the Big Five Hospital. According to related industries, Lorviqua of Pfizer Korea passed the Drug Committee of Big 5 (DC), excluding Seoul St. Mary's Hospital such as Samsung Medical Center, Seoul National Cancer Center, and Chung-Ang University Hospital. As the adequacy of insuranc
- Company
- Janssen takes sole lead in the ₩50 billion PAH market
- by Kim, Jin-Gu May 27, 2022 05:56am
- Janssen Korea is solidifying its lead in the &8361;50 billion pulmonary arterial hypertension market in Korea. Whether the company will be able to maintain the share it has built up so far after terminating the co-promotion agreement with Handok remains a large variable. ◆The market for the rare disease pulmonary arterial hypertension
- Company
- Tremfya reimb. expanded to psoriatic arthritis
- by Eo, Yun-Ho May 27, 2022 05:56am
- The IL-23 inhibitor 'Tremfya’ is now applied insurance benefit in psoriatic arthritis. The Ministry of Health and Welfare issued a notice of amendment and extended the reimbursement standard of Tremfya as of the first of this month. With the amendment, Tremfya may now be reimbursed in patients with active or progressive psoriatic arth
- Company
- Soliris to Ultomiris...generation shift picks up speed
- by Kim, Jin-Gu May 26, 2022 05:56am
- The generation shift between Handok’s paroxysmal nocturnal hemoglobinuria treatments Soliris (eculizumab) and Ultomiris (ravulizumab) is gaining speed. With Ultomiris quickly replacing Soliris, Handok’s strategy of checking the release of Soliris’s biosimilars is also being considered a success. ◆Sales of Soliris drop 75%… replaced
- Company
- Avastin’s Q1 sales drop sharply… future sales prospects?
- by May 25, 2022 05:47am
- Roche’s blockbuster anticancer drug ‘Avastin (bevacizumab) has recorded the lowest quarterly sales in 5 years. The drug had been much influenced by the drug price cut that followed the introduction of its biosimilars. However, whether the drop will continue remains to be seen due to the rise of new variables from the additional price cut a
- Company
- Yuhan Leclaza's first-quarter sales were 3.2 billion won
- by Chon, Seung-Hyun May 24, 2022 05:55am
- Yuhan's new anticancer drug Leclaza posted sales of 3 billion won in the first quarter. It has continued to rise since it entered the domestic market in earnest in the second half of last year. It is expected to surpass 10 billion won in annual sales for the first time among new anti-cancer drugs developed in Korea. According to IQVIA, on the
- Company
- Duodart may be prescribed at general hospitals in Korea
- by Eo, Yun-Ho May 24, 2022 05:55am
- The combination drug ‘Duodart’ that contains ‘dutasteride’ and ‘tamsulosin’ may be prescribed in general hospitals in Korea. According to industry sources, Duodart, GSK Korea’s fixed-dose combination drug for benign prostatic hyperplasia (BPH), has recently passed the drug committee (DC) review of Sinchon Severance Hospital and is
- Company
- Janssen makes first bid into lung cancer mkt with Rybrevant
- by May 24, 2022 05:55am
- “We will work to make Rybrevant, which had been first approved to treat EGFR exon 20 insertion mutations, the No.1 option for lung cancer patients in Korea.” Janssen Korea expressed so at the press conference that was held on the 23rd to celebrate the launch of Rybrevant in Korea. Rybrevant (amivantamab) received marketing authorization
- Company
- Alvogen, 1 in 3 failed patent attempts for Avastin
- by Kim, Jin-Gu May 24, 2022 05:55am
- Alvogen Korea failed to cross the last hurdle in the Roche anticancer drug Avastin patent challenge. It challenged three patents, but succeeded in overcoming only two and failed one. The Korean Intellectual Property Tribunal recently dismissed the Avastin patent invalidation trial filed by Alvogen Korea against Roche. As a result, the orig
